Off-label prosecutors target devices

Share this article:
In what may signal a new wave of government investigations, the US Attorney's Office in Philadelphia has issued a grand jury subpoena to a device firm— PA-based Synthes—over alleged off-label promotion practices.

Until now, off-label prosecutorial cases had been limited to drug makers. But prosecutors warned last October that their investigations were likely to spill over into the device arena. 

HHS Office of the Inspector General senior counsel Jnatel Simmons says most government actions against medical device firms originate as qui tam actions or whistleblower lawsuits under the False Claims Act, which prohibits falsified claims for payment from being submitted to the government. 
The latest subpoena demands that Synthes supply information on alleged off-label promotion practices involving its bone void filler Norian XR and related products.

Norian XR was cleared by the FDA in 2002 for its intended use on certain bony voids or defects that are not intrinsic to the stability of the bony structure. 

The product was removed from the market in November 2004 after an FDA inspection and subsequent Warning Letter charged the company was marketing Norian XR for new intended uses without FDA approval.
Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Features

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?